Edition:
United Kingdom

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

30.92USD
16 Feb 2018
Change (% chg)

$-0.14 (-0.45%)
Prev Close
$31.06
Open
$31.00
Day's High
$31.53
Day's Low
$30.83
Volume
179,262
Avg. Vol
487,500
52-wk High
$41.20
52-wk Low
$25.06

Chart for

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease... (more)

Overall

Beta: 3.76
Market Cap(Mil.): $4,717.31
Shares Outstanding(Mil.): 122.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Acadia Pharmaceuticals posts Q3 loss of $0.53 per share

* Acadia Pharmaceuticals reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin

* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis

04 Oct 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
Eli Lilly and Co (LLY.N) $78.97 +0.95
Eisai Co., Ltd (4523.T) ¥5,575 +61.00

Earnings vs. Estimates